Calvin Sandra

CAO Calvin Sandra sold 67.1K TVTX shares at $36.00 for $2.4M, reducing holdings by 58%; prior 5 TVTX sells all well-timed with negative 90-day returns.

Calvin Sandra, SVP and Chief Accounting Officer, divested 67,115 shares (67.1K shares) at $36.00 on 2025-11-04, reducing his holdings by 58.0% from 115,660 to 48,545 shares. His prior trading history at TVTX is notable: all 5 preceding sales occurred on 2025-02-11 and were well-timed, each producing negative 90-day returns of -13.8%, meaning the stock declined after those sales. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 5 prior sells, with an average 90-day return of -13.8%. The current stock price of $33.30 reflects a 5.3% decline from the 52-week high of $35.16, while the 30-day and 90-day returns of +30.6% and +96.6% respectively show the stock is substantially elevated from recent lows. The timing and scale of this sale—reducing his stake by more than half—warrant monitoring given the insider's consistent track record of selling ahead of subsequent declines.

CFO Calvin Sandra sold 54,244 shares for $1,356,100 at TVTX; reduced stake by ~50% as company faces -31.5% revenue decline and $54.8M annual loss

Calvin Sandra, SVP Chief Accounting Officer at Travere Therapeutics, executed 5 separate sales totaling 54,244 shares for $1,356,100.00 on 2025-02-11, reducing his holdings by approximately 50% from 108,654 shares to 54,410 shares. The sales occurred at $25.00 per share while the stock currently trades at $23.20, down -2.3% from its 52-week high of $23.75. The divestiture is notable given the company's deteriorating fundamentals: annual revenue declined -31.5% year-over-year, the company posted a net loss of $54,811,000.00 in its most recent full fiscal year, and the latest quarterly revenue stands at $62,898,000.00 with a loss of $54,811,000.00. A substantial reduction of executive equity stakes during a period of negative earnings growth and revenue contraction warrants investor attention regarding confidence in the company's near-term trajectory.